Creutzfeldt–Jakob disease in a post-COVID-19 patient: did SARS-CoV-2 accelerate the neurodegeneration?

• Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery Vol. 59; no. 1; pp. 69 - 7
• Main Authors: Alloush, Taha K., Alloush, Adel T., Abdelazeem, Yaser, Shokri, Hossam M., Abdulghani, Khaled O., Elzoghby, Ahmed
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 22.05.2023; Springer Nature B.V; SpringerOpen
• Subjects: Alzheimer's disease; Case Report; Case reports; COVID-19; Dementia; Disease transmission; Encephalitis; Iatrogenesis; Immune response; Laboratories; Medicine; Medicine & Public Health; Nervous system; Neurodegeneration; Neurodegenerative disorder; Neurology; Neurosurgery; Pathogenesis; Patients; PET/MRI brain; Psychiatry; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Sleep apnea; Sporadic Creutzfeldt–Jakob disease (sCJD); COVID-19; Neurodegenerative disorder; SARS-CoV-2; PET/MRI brain; Sporadic Creutzfeldt–Jakob disease (sCJD)
• ISSN: 1110-1083; 1687-8329
• DOI: 10.1186/s41983-023-00666-y

Background Creutzfeldt–Jakob disease (CJD) is a rare, fatal neurodegenerative disorder, with few months as a usual duration from onset to death. Case presentation In this case report, a patient of Sporadic CJD (sCJD) who presented one month after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. The diagnosis of this case was established after confirming findings from clinical, neurophysiology, radiological, and laboratory features of this disease. Conclusion Putting in mind all the updated data on the pathogenesis of CJD and the immune responses to SARS-CoV-2, we can suggest that COVID-19 can lead to accelerated pathogenesis and exaggerated manifestations of this fatal neurodegenerative disease.